{"id":"NCT00561925","sponsor":"Boehringer Ingelheim","briefTitle":"VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients","officialTitle":"A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2011-11","completion":null,"firstPosted":"2007-11-21","resultsPosted":"2012-01-19","lastUpdate":"2014-04-07"},"enrollment":1068,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"nevirapine IR","otherNames":[]},{"type":"DRUG","name":"nevirapine XR","otherNames":[]}],"arms":[{"label":"nevirapine XR","type":"EXPERIMENTAL"},{"label":"nevirapine IR","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.","primaryOutcome":{"measure":"Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population","timeFrame":"week 48","effectByArm":[{"arm":"NVP IR 200mg BID","deltaMin":384,"sd":null},{"arm":"NVP XR 400mg QD","deltaMin":409,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":202,"countries":["United States","Argentina","Australia","Belgium","Botswana","Canada","France","Germany","Ireland","Italy","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Russia","South Africa","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["21817198"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":1068},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Rash","Upper respiratory tract infection"]}}